Filter posts

The Administration’s Orwellian Defense of Importing Foreign Price Controls

The Trump administration is out with a new blog post defending its plan to adopt …

Think the Drug-Pricing debate addresses Patient Costs? Think again.

Writing for The Hill, BIO President and CEO Jim Greenwood tackled the drug pricing debate …

Hits to Patients Keep on Coming

At a time when prescription drug prices and spending are remarkably stable, patients are getting …

On the President’s Drug Cost Plan, Three Important Concerns

Part 3. Restricting access under Medicaid Is not the answer This week, BIO launched a …

On the President’s Drug Cost Plan, Three Important Concerns

Part 1. Restricting access under Medicare Part D  The Trump administration is out with its …

New Infographic Highlights the Remarkable Success of Medicare Part D

Since 2006, the Medicare prescription drug program – known as Medicare Part D – has …

A Flawed Bill That Would Harm Seniors

The Medicare prescription drug program has been a remarkable success for both seniors and taxpayers, …

If It Isn’t Broke …

Congress created the Medicare Part D prescription drug program in 2003, and for more than …

ICYMI: Op-Ed by Rep. Gus Bilirakis on Lowering Drug Costs

Yesterday, U.S. Representative Gus Bilirakis of Florida published an op-ed outlining how to “Lower Drug …

Health Affairs Study: Want to save money in Medicaid? Increase adherence.

At BIO, we have long argued that the use of prescription medicines can yield substantial …